



**HAL**  
open science

## Pharmacokinetics of natural mistletoe lectins after subcutaneous injection

Roman Huber, Jürgen Eisenbraun, Barbara Miletzki, Michael Adler, Rainer Scheer, Reinhild Klein, Christoph H. Gleiter

► **To cite this version:**

Roman Huber, Jürgen Eisenbraun, Barbara Miletzki, Michael Adler, Rainer Scheer, et al.. Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. *European Journal of Clinical Pharmacology*, 2010, 66 (9), pp.889-897. 10.1007/s00228-010-0830-5 . hal-00593327

**HAL Id: hal-00593327**

**<https://hal.science/hal-00593327>**

Submitted on 14 May 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Pharmacokinetics of natural mistletoe lectins after subcutaneous injection**

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2009-0404.R1
Type of submission:	Original
Date Submitted by the Author:	13-Apr-2010
Complete List of Authors:	Huber, Roman; University Hospital Freiburg, Environmental Health Sciences Eisenbraun, Jürgen; Abnoba GmbH, Abnoba GmbH Miletzki, Barbara; CenTrial, CenTrial Adler, Michael; Chimera Biotec GmbH, Chimera Biotec GmbH Scheer, Rainer; Abnoba GmbH, Abnoba GmbH Klein, Reinhild; Department of Internal Medicine II, University of Tübingen Gleiter, Christoph; CenTrial, CenTrial

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Pharmacokinetics of natural mistletoe lectins after subcutaneous injection

Roman Huber<sup>1</sup>, Jürgen Eisenbraun<sup>2</sup>, Barbara Miletzki<sup>3</sup>, Michael Adler<sup>4</sup>, Rainer Scheer<sup>2</sup>,  
Reinhild Klein<sup>5</sup>, Christoph H. Gleiter<sup>3</sup>

<sup>1</sup> Department of Environmental Health Sciences, University Hospital Freiburg, Germany

<sup>2</sup> Abnoba GmbH, Pforzheim, Germany

<sup>3</sup> CenTrial GmbH, Tübingen/Ulm, Germany

<sup>4</sup> Chimera Biotec GmbH, Dortmund, Germany

<sup>5</sup> Department of Internal Medicine II, University of Tübingen, Germany

Corresponding author

Dr. Roman Huber

Department of Environmental Health Sciences

University Hospital Freiburg

Breisacher Str. 115b

D-79106 Freiburg

Germany

Phone: 0049 761 270 8201

Fax: 0049 761 270 8323

Email: roman.huber@uniklinik-freiburg.de

**Abstract**

**Purpose:** Knowledge of natural mistletoe lectins (nML) pharmacokinetics can be regarded as essential for further rational studies with mistletoe preparations. Studies with intravenous application of a recombinant type II ribosome inactivating protein (rML) analogous to nML revealed a short half life of about 13 minutes in cancer patients. This open-label, phase I, monocenter clinical trial was performed in order to describe the pharmacokinetics of nML.

**Methods:** In 15 healthy male volunteers aged 18-42 years nML were detected with a modified sandwich Immuno-PCR technique (Imperacer®, Chimera Biotec) after single subcutaneous injection of a mistletoe extract (abnobaVISCUM® Fraxini 20mg) with marketing authorisation, containing about 20µg nML per millilitre. Secondary objectives were safety and the number of activated natural killer cells (CD54+/CD94+).

**Results:** In none of the volunteers nML were detectable before the injection and in all volunteers nML were detected in serum samples after the injection. Individual variability however was large. The mean and median peak concentration was reached 1 and 2 hours after injection, respectively. In some of the volunteers nML were still detectable at the final investigation 2 weeks after injection. The injection resulted in fever and flue like symptoms in all volunteers but no serious adverse events occurred. All symptoms and local reactions at the injection site completely disappeared within a range of 4 to 95 days. The number of activated natural killer cells did not change.

**Conclusions:** nML from abnobaVISCUM® Fraxini 20mg are detectable in serum after a single subcutaneous injection. Detectability is considerably longer compared to intravenous. rML. The subcutaneous injection of this preparation without usual pre-treatment with lower doses results in short-lasting fever and other flu-like symptoms.

**Key words:**

abnobaVISCUM, anthroposophical medicine, healthy volunteers, phytotherapy, safety, NK-cells

## Introduction

Mistletoe preparations are used since decades for supportive cancer treatment within the concept of anthroposophical medicine. Despite more than 40 randomized clinical trials, the efficacy of mistletoe treatment in cancer therapy is yet not clear and discussed controversially [1]. Reasons for this unsatisfactory situation are, that different mistletoe preparations with different ingredients in different concentrations have been tested and that the pharmacology of mistletoe extracts is unclear. Active ingredients of mistletoe extracts are mainly mistletoe lectins (nML), viscotoxins and polysaccharides. From these, nML are the most interesting substances for anticancer activity. They have in in-vitro and animal models been demonstrated to have distinct cytotoxic properties [2, 3]. In doses below cytotoxicity nML stimulate the unspecific and specific immune system in humans [4].

ML are glycoproteins and occur naturally in 2 types, the ribosome inactivating proteins of class 2, which are divided in the 3 subtypes nML-I, -II and -III and viscum album chitin-binding ML (cbML). The molecular weight of nML I-III is about 63 kDa. They have very similar biological properties and are composed of a N-glycosidase (A-chain) and a galactoside-recognizing lectin (B-chain), connected by a disulfide bridge [5, 6]. The A-chain inhibits protein synthesis [7, 8]. The B-chain binds to carbohydrate residues on the cell surface, thus entering the cell by receptor-mediated endocytosis and inducing apoptosis of the cell [8, 9]. The cbML belongs to a different class of lectins with a different structure, low antigenicity and a molecular weight of only about 11 kDa [10]. It is far less toxic than nML I-III and is not included in our analysis.

Recently, the technique to detect nML I-III in nanogram ranges in human serum has been developed [11, 12]. A recombinant type II ribosome inactivating protein (rML) analogous to natural mistletoe lectin I revealed a short half life of about 13 minutes in cancer patients [12]. Knowledge of nML pharmacokinetics can be regarded as important to optimize clinical use and further rational studies with mistletoe preparations. To the first time, we therefore investigated the pharmacokinetics of natural mistletoe lectin from a commercially available mistletoe preparation in humans.

## Patients and Methods

The study was performed as an uncontrolled, non-randomized, open-label, phase I, mono-center clinical trial. Primary outcome was the pharmacokinetics of  $\eta$ ML following a single dose (1 ml) of subcutaneously administered abnobaVISCUM<sup>®</sup> Fraxini 20mg in healthy male volunteers. Secondary outcomes were safety and activation markers (CD54+/CD94+) on natural killer (NK) cells. This marker was selected, because treatment of patients with metastatic colorectal cancer and lung cancer with NK-cells (CD54+/CD94+) activated by heat shock proteins showed promising anti-tumor effects [13]. We wanted to test the hypothesis, that mistletoe-induced fever activates NK-cells.

The study comprised a screening (examination 1), a period of hospitalisation (examination 2 to 6) from the night before until 72 hours after s.c. injection of the IMP (investigational medicinal product) and a final follow-up (examination 7) on day 14 +/- 3 after injection of the IMP.  $\eta$ ML-concentrations in volunteers' sera were analysed before and 0.3, 0.7, 1.0, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48, 72 and 336 hours after injection of the IMP. Safety laboratory parameters (creatinine, urea, uric acid, sodium, potassium, chloride, calcium, creatine kinase, alanin amino transferase (ALT), aspartate amino transferase (AST), lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl-transferase, total bilirubin, total protein, albumin, alpha-amylase, C-reactive protein (CRP), cholesterol, triglycerides, glucose) were determined at examinations 1, 2, and 7. CD54+/CD94+ NK cells were determined before and 6, 24 and 72 hours after injection of the IMP.

Inclusion criteria were: 18-45 years old non smoking healthy males, body mass index 18.5-28 kg/m<sup>2</sup> with normal values for blood pressure, pulse rate, body temperature, normal haematological, biochemical and coagulation parameters and normal electrocardiogram. Exclusion criteria were signs of any clinically significant disease, regular use of medication, drug abuse, positive urine screening for drugs, positive blood test for ethanol, participation in another clinical trial, previous therapy with mistletoe preparations, history of allergy to a medicinal product, allergic diseases except the investigator considered them as clinically irrelevant for the purpose of this clinical trial, positive HIV, hepatitis B or C serology, regular intake of more than 20g ethanol per day, donation of blood within 3 months prior to study entry, difficult peripheral venous access and inability to understand the nature and the extent of the trial.

1  
2 Only volunteers who gave written informed consent and met all eligibility criteria were  
3 included into the study.

4  
5 The relevant ethics committee had provided a favourable opinion on the clinical trial prior to  
6 study start and the study was performed in compliance with the principles of Good Clinical  
7 Practice and the Declaration of Helsinki.  
8  
9

#### 10 Medication

11  
12 AbnobaVISCUM<sup>®</sup> Fraxini 20mg is an injectable, endotoxin free plant extract from the  
13 European mistletoe species *Viscum album* L. for the treatment of malignant tumors, tumor  
14 recurrences and defined precanceroses. As abnobaVISCUM<sup>®</sup> Fraxini 20 mg has the highest  
15 content of nML (approx. 20.000ng/ml) of all commercially available mistletoe preparations,  
16 this preparation was chosen in order to detect nML in the nanogram range after subcutaneous  
17 injection. Mistletoes from deciduous trees like the ash tree, from which abnobaVISCUM<sup>®</sup>  
18 Fraxini is derived, have relatively high proportions of nML I in relation to nML II/III [14] but  
19 due to methodological difficulties, no differentiation of the MLs could be performed in the  
20 commercial extract. The amount of cbML in abnobaVISCUM<sup>®</sup> Fraxini 20 mg has been about  
21 1µg/ml [15]. Each volunteer was given the same single dose (1 ml) of subcutaneously  
22 administered abnobaVISCUM<sup>®</sup> Fraxini 20mg. No dose adjustments were necessary, since the  
23 inclusion criteria limited the body mass index of the volunteers to a range of 18.5-28 kg/m<sup>2</sup>.  
24  
25 Intratumoral injections with abnobaVISCUM<sup>®</sup> Fraxini 20 mg resulted in highly significant  
26 tumor reductions in human pancreatic cancer xenografts [3].  
27  
28  
29  
30  
31  
32  
33  
34

#### 35 Quantification of nML and activated NK-cells

36 Each blood sample was put on ice immediately after collection and centrifuged for 10 minutes  
37 at 4°C and 2500xg. Thereafter, at least 2 ml of serum were immediately frozen and stored at  
38 -80°C in the clinical trial center.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

nML in the sera of the volunteers was measured by an ultrasensitive immuno-PCR method (Imperacer<sup>®</sup>) [11, 12, 16], which combines protein detection through ELISA with the exponential signal amplification typical for PCR. The method was validated by Chimera Biotech GmbH, Dortmund, Germany for natural mistletoe lectins of abnobaVISCUM<sup>®</sup> in human serum. It does not discriminate between the nML subtypes I-III. Due to the completely different structure it does not detect cbML. Briefly, the antigen was immobilized on capture-antibody coated microplate surfaces directly from the serum samples as delivered for analysis without additional purification. For minimization of background effects, the samples were diluted 1:3 in a detergent-containing sample dilution buffer. Parallel to the samples, a dilution series of the antigen was studied, abnobaVISCUM<sup>®</sup> Fraxini 20 mg, batch no. 407B04 and abnobaVISCUM<sup>®</sup> Mali 20 mg, batch no. 502B33 (both ABNOBA GmbH, Germany) were used as reference substance. Spiked samples were used as a calibration curve for quantification of the antigen and testing robustness and specificity. Each calibration curve (6000 – 93.75 pg/ml antigen) was prepared in antigen-free individual serum, taken previous to the application of the antigen. This dilution series was additionally frozen to simulate the effect of freezing on the antigen-containing samples for analysis. Following incubation of the samples and the calibration curve, the immobilized antigen was coupled with a specific antibody-DNA conjugate. The assay was carried out with a lectin-specific tailored Imperacer<sup>®</sup> Kit (No. 11-030, Chimera Biotec, Germany). Monoclonal mouse-anti-ML antibody 5F5, anti-ML-I-(A-Chain) and 5H8 Anti-ML-A (Institut für Immunopräparate und Nährmedien GmbH, , Germany) were used as detection- and capture antibody, respectively.

After a washing step the DNA-marker was amplified by real-time PCR. In data analysis, a baseline correction was applied. The instrument software calculates the threshold cycle (Ct), which represents the first PCR cycle at which the reporter signal exceeds the signal of the baseline (“threshold”), and sets it in the phase where the signal increases linearly. Baseline correction and threshold were identical in all validation measurements.  $\Delta$ Ct values were calculated by subtracting the Ct values obtained for each signal from the total number of cycles carried out in the experiment. This purely mathematical conversion facilitates the comparison of the data with conventional ELISA data as  $\Delta$ Ct values are directly proportional to the antigen concentration.



1  
2 Assay precision, sensitivity, specificity and robustness were suitable for this pharmacokinetic  
3 study. A linear concentration range of the Imperacer<sup>®</sup> assay was validated from 0.1-100 ng  
4 nML/ml. Regarding a dose of 20.000 ng nML and approximately 3000 ml serum in humans a  
5 maximum concentration of 6.6 ng nML/ml was expected to be measured, if 100% of injected  
6 nML would have been distributed equally and immediately in the blood circulation without  
7  
8 metabolisation. With a linear measurement range starting at 0.1 ng it was possible to measure  
9  
10 a quantitative nML concentration if only 5 % of the injected amount of 1 ml  
11 abnobaVISCUM<sup>®</sup> Fraxini 20 mg appeared in the blood circulation at one sample timepoint.  
12 This was expected to be low enough for a successful detection of the kinetic parameters. 0.1  
13 ng nML/ml was the cut off value, from which on nML concentrations were positive.  
14  
15  
16

17  
18 For the determination of NK cells, heparinized blood was used, and peripheral blood  
19 mononuclear cells (PBMC) were isolated by Ficoll-gradient. After staining with PE-  
20 conjugated anti-CD56, PerCP-conjugated anti-CD45 and FITC conjugated anti-CD94  
21 antibodies (all obtained from Becton-Dickinson [San Jose, CA]) the PBMC were incubated  
22 with the respective antibodies or IgG isotype control antibodies (BD Biosciences  
23 Pharmingen). A minimum of 10 000 lymphocytes were counted. Quadrants were set based  
24 upon the isotype controls for each antibody.  
25  
26  
27  
28

#### 29 30 Statistics

31 No comparison with a control group was planned and no data for comparison did exist. Since  
32 the study was to be conducted for exploratory purposes no statistically based sample size  
33 calculation was performed. It was planned to include n=16 (two groups of n=8) healthy male  
34 volunteers into the trial, because this is a sufficient number to enable evaluation of the single  
35 dose-pharmacokinetics of abnobaVISCUM<sup>®</sup> Fraxini 20mg.  
36  
37

38 For statistical analyses two populations of clinical trial participants were defined:

- 39 1) The pharmacokinetic population which had to include all clinical trial participants who  
40 provided evaluable and interpretable pharmacokinetic results during the 72 hrs after dosing of  
41 abnobaVISCUM<sup>®</sup> Fraxini 20mg.  
42
- 43 2) The safety population which had to encompass all clinical trial participants who met all  
44 eligibility criteria and were included in the clinical trial.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 The analyses of the nML-pharmacokinetics and the immunological activation marker had to  
3 be performed on the pharmacokinetic population. The evaluation of safety and tolerability had  
4 to be performed on the safety population. Missing or manipulated data had to be corrected if  
5 possible. If this was not possible the data were to be treated as missing data.  
6  
7

## 8 9 Results

10  
11  
12 N=35 volunteers were screened and n=20 were found to be eligible for the study. Deviating  
13 from the originally planned sample size of n=16, only n=15 were administered the IMP. 5 had  
14 to be excluded before IMP administration due to newly developed exclusion criteria between  
15 screening and hospitalisation. Demographics of the volunteers are shown in table 1. nML  
16 were detectable in none of the volunteers before and in all volunteers after injection of the  
17 IMP. Although all volunteers received the s.c. injection of the IMP from the same  
18 experienced investigator, individual serum concentration-time profiles varied considerably:  
19 Volunteers No 1 to 9 and 14 (10/15 volunteers (67%) showed a fast increase with high  
20 concentrations of nML followed by a slow decrease. A second increase was observed in  
21 volunteers No 2, 5, 9 and 14 (4/15, 27%). The remaining 5/15 volunteers (33%), i.e. volunteers  
22 No 10 to 13 and 15, had an undulating course with low levels of nML-concentrations. At the  
23 final examination (day 14 +/- 3 days after injection) serum nML-concentrations were not  
24 detectable in 5/15 volunteers but 9/15 volunteers (60%) had still measurable nML-  
25 concentrations. For one volunteer the last scheduled nML-concentration could not be  
26 determined because he did not appear to the last examination. The course of nML-  
27 concentrations is shown in Figure 1, the pharmacokinetic data are presented in Table 2 and 3.  
28 The mean serum peak concentration was observed at 01:00 hour post-dose. By the end of the  
29 study the curve had not yet, but almost returned to pre-dose values.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 The arithmetic means of  $C_{\max}$  and  $AUC(0-\infty)$  amounted to 1043pg/ml and 8395 h\*pg/ml,  
3 respectively.  $t_{\max}$  ranged from 0.3 to 336.0 hours with a median of 2.0 hours. A calculated  
4 concentration of 3.7 ng  $\mu$ ML/ml for the highest signal of the study as determined in volunteer  
5 No 3, 1h after injection corresponds to 56% serum-availability for this time point (100% = 6.6  
6 ng/ml). Calculation of  $\lambda_z$  and  $t_{1/2}$  ( $t_{1/2} = \ln 2 / \lambda_z$ ) was in none of the volunteers possible due to  
7 non-linear concentration-time profiles. The  $AUC(0-t_{\text{last}})$  was determined by trapezoidal  
8 analysis. In volunteers No. 2, 3, 9 -13 and 15,  $AUC(t_{\text{last}}-\infty)$  could not be determined because  
9 the  $\mu$ ML-concentration-time curves could not be extrapolated to  $\infty$  due to non-linearity. In  
10 volunteers No. 1, 4 to 8 and 14,  $AUC(t_{\text{last}}-\infty)$  did not need to be determined because  $\mu$ ML-  
11 concentrations decreased below detection threshold within the time period of blood sampling.  
12 For volunteers in whom the  $\mu$ ML serum concentrations had not decreased below detection  
13 threshold of 100pg/ml in the time period of blood sampling, i.e. for 10/15 volunteers (67%),  
14  $AUC(0-\infty)$  and  $CL_{\text{sc}}(0-\infty)$  were not determinable.  
15  
16  
17  
18  
19  
20  
21  
22

23 Compared to baseline, activated NK-cells (CD54+/CD94+) as proportion of total NK-cells  
24 (CD16+/CD56+) did not significantly change after injection of the IMP.  
25

26 There were no serious adverse events whether drug-related or not. 53/55 treatment emergent  
27 AEs were assessed by the investigator to be at least possibly related to the IMP and all 15  
28 volunteers experienced one or more AE with at least possible causal relationship to the IMP.  
29 Only 3/55 treatment emergent AEs observed in 2/15 volunteers (13 %) were of severe  
30 intensity (flue-like symptoms in 2, nausea in 1 volunteer).  
31  
32  
33

34 As expected, a local inflammatory reaction at the injection site of abnobaVISCUM<sup>®</sup> Fraxini  
35 20mg was observed in almost all study participants (14/15 volunteers, 93%) and 15/15  
36 volunteers had an increase of body temperature to  $>37.5^{\circ}\text{C}$  (Figure 2) which was  
37 accompanied by flu like symptoms in all and nausea in 8 volunteers. 11/15 volunteers (73.5  
38 %) took concomitant medication because of pain at the injection site during hospitalisation  
39 and 3/15 volunteers also after discharge from the clinical trial center. In 12/15 volunteers (80  
40 %) the inflammatory reaction persisted beyond the final study examination the longest  
41 duration of the reaction amounting to 95 days.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 With regard to laboratory evaluations, no clinically significant deviations of haematological,  
3 biochemical and urinalysis parameters from the normal range were observed at the final  
4 examination (day 14+/-3 days) after administration of the IMP (Table 4). None of the  
5 volunteers showed a clinically significant abnormality in the ECG throughout the study. Apart  
6 from the above described local inflammatory reactions at the injection site no clinically  
7 significant abnormalities were found during the physical examination.  
8  
9

## 10 Discussion

11  
12 This study investigated for the first time pharmacokinetics of naturally occurring [mistletoe](#)  
13 [lectins](#) from a commercially available nML-rich mistletoe extract. The main findings were:  
14

- 15 1. nML from mistletoe extracts can be detected in the human serum after a single  
16 subcutaneous injection.
- 17 2. Detectability of nML in serum is considerably longer than that of recombinant type II  
18 ribosome inactivating protein (rML) analogous to mistletoe lectin.
- 19 3. Pharmacokinetics of nML after subcutaneous injection is subject to considerable inter-  
20 individual variability.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Due to non-linear kinetics the half-life of nML could not be determined, since calculation of  
31 half-life is meaningless in case of non-linear concentration-time-profiles. Because half-life of  
32 rML is only 13 minutes [12] and in 9/15 of our volunteers nML was detectable even two  
33 weeks after injection, a longer detectability of nML in serum can be concluded, even though  
34 the route of application was intravenous in the study of Schöffski et al. and subcutaneous in  
35 our study. In contrast to rML, nML is glycosylated and has different kinetics of association  
36 and dissociation with glycoconjugates. Furthermore, B-chains of rML and nML differ in  
37 binding specificity to carbohydrates [17]. This may cause different uptake and distribution in  
38 blood and tissue and could explain the longer detectability of nML in serum. Cytotoxicity of  
39 nML and rML were similar in MOLT-4 cell cultures [17]. In vitro studies using human  
40 peripheral blood mononuclear cells, however, significant differences of rML and nML on cell  
41 viability and immunomodulation were found [18].  
42  
43  
44  
45  
46  
47

48 A long detectability in serum regarded as advantageous for therapeutic use might be opposed  
49 by the strong interindividual differences of nML pharmacokinetics after subcutaneous  
50 injection.  
51  
52

1  
2 The high interindividual differences that were observed although all volunteers were injected  
3 by the same investigator in the same abdominal quadrant may be attributed to different  
4 patterns of nML binding to carbohydrates and release from the subcutaneous tissue. The  
5 observed non-linear pharmacokinetics of the large nML molecules (50-63kDa) would support  
6 this hypothesis. Pharmacokinetic investigations in rats, performed within a subchronic  
7 toxicity study with abnobaVISCUM<sup>®</sup> Fraxini 20mg also showed high interindividual  
8 differences between the animals under GLP-conditions [19]. Cross-reactivities could  
9 potentially have affected the test results but are unlikely. Cross-reactivity to cbML can be  
10 excluded because of its completely different structure and because comparing experiments  
11 with antibodies to nML I-III and cbML in healthy volunteers and tumor patients did not show  
12 cross-reactivity [10]. Because nML I-III is highly antigenic after parenteral injection (almost  
13 100% of nML exposed individuals develop anti-nML antibodies) and anti-nML antibodies are  
14 absent in individuals without previous exposure to parenteral mistletoe preparations [20], a  
15 cross reactivity to environmental factors like diet or inhalative environmental antigens can  
16 also widely be excluded. Metabolites of nML are, to our knowledge, not known.

17 We choose the subcutaneous application, because this is the common form for mistletoe  
18 preparations and abnobaVISCUM<sup>®</sup> Fraxini 20mg has only the marketing authorisation for  
19 subcutaneous injection. Also pharmacokinetics of other molecules, like soluble, recombinant  
20 interleukin-4 receptor (sIL-4R)[21] and erythropoietin [22], with a size comparable to nML of  
21 140- and 34 kDa, respectively, were investigated after subcutaneous (s.c.) injection. Murine  
22 sIL-4R elimination half life was 2.3 hours following intravenous injection and 6.2 hours after  
23 s.c. injection. Also the sIL-4R blood level was lower after s.c. injection but bioavailability  
24 was comparable. Subcutaneously applied erythropoietin, given to 48 volunteers, resulted in  
25 considerable inter-individual differences of C<sub>max</sub> from 40 to 95 IU/l. The half life was about 3  
26 times longer than after intravenous application. Despite the comparability with these  
27 endogenously occurring substances is limited, the findings of a longer detectability and higher  
28 inter-individual differences are in principle in accordance with our results.

29 Initial high doses of subcutaneously applied abnobaVISCUM<sup>®</sup> Fraxini 20 mg have a variety  
30 of side effects, especially fever and related symptoms and strong local reactions. The  
31 manufacturer recommends, therefore, lower doses for initial therapy. In one publication,  
32 however, even higher doses (2 ampoules abnobaVISCUM<sup>®</sup> Fraxini 20mg) were applied  
33 initially and had beneficial effects in 23 patients with advanced hepatocellular carcinoma [23].  
34 The non-hematological toxicity included fever, erythema and pain at the injection site as in  
35 our volunteers. No hematological toxicity was observed. This published clinical experience  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 encouraged us to regard 1 ampoule abnobaVISCUM® Fraxini 20 mg as safe for this phase I  
3 pharmacokinetic study. The hypothesis, that the percentage of activated NK-cells  
4 (CD54+/CD94+) increases after a single injection of abnobaVISCUM® Fraxini 20mg could  
5 not be confirmed.  
6  
7

8 Since it is now known that natural mistletoe lectins are absorbed into the blood after  
9 subcutaneous injection of abnobaVISCUM® Fraxini 20mg in healthy volunteers,  
10 pharmacokinetic considerations should also be addressed in subsequent clinical trials with  
11 mistletoe preparations for oncological patients.  
12  
13

#### 14 15 Acknowledgment

16  
17 The study was sponsored by Abnoba GmbH, Pforzheim, Germany.  
18  
19  
20  
21  
22  
23

#### 24 25 References

- 26  
27 1. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in  
28 oncology. Cochrane Database Syst Rev (2):CD003297
- 29  
30 2. Ribéreau-Gayon G, Jung ML, Frantz M, Anton R (1997) Modulation of cytotoxicity  
31 and enhancement of cytokine release induced by Viscum album L. extracts or  
32 mistletoe lectins. Anticancer Drugs 8 Suppl 1:S3-8
- 33  
34 3. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH (2005)  
35 Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into  
36 human pancreatic cancer xenografts. Anticancer Res 25(3B):1969-1975
- 37  
38 4. Huber R, Rostock M, Goedel R, Lüdtke R, Urech K, Buck S, Klein R (2005) Mistletoe  
39 treatment induces GM-CSF- and IL-5 production by PBMC and increases blood  
40 granulocyte- and eosinophil counts: a placebo controlled randomized study in  
41 healthy subjects. Eur J Med Res 10(10):411-418
- 42  
43 5. Franz H (1985) Inhaltsstoffe der Mistel (Viscum album L.) als potentielle Arzneimittel.  
44 Pharmazie 40:97-104
- 45  
46 6. Franz H (1991) Mistletoe lectins (2). In: Franz, H (ed) Advances in Lectin Research,  
47 Springer Berlin, pp 33-50  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
7. Franz H, Friemel H, Buchwald S, Plantikow A, Kopp J, Körner I.J (1990) The A chain of lectin 1 from European mistletoe (*Viscum album*) induces interleukin-I and interleukin-II in human mononuclear cells. In: Kocourek J, Freed DLJ (eds) *Lectins: Biology, Biochemistry, Clinical Biochemistry* Vol. 7, Sigma Chemical Company, St. Louis, Missouri, USA, pp. 247-250
8. Stirpe F, Barbieri L, Batteli MG, Soria M, Lappi DA (1992) Ribosome-inactivating proteins from plants: present status and future prospects. *Bio Technology* 10:405-412
9. Büssing, A (2000) Biological and pharmacological properties of *Viscum album* L. In: Büssing, A (ed) *Mistletoe, the Genus *Viscum**. Amsterdam (2000)
10. Klein R, Franz M, Wacker R, Classen K, Scheer R, Von Laue HB, Stoeva S, Voelter W (2004) [Demonstration of antibodies to the chitin-binding mistletoe lectin \(cbML\) in tumor patients before and during therapy with an aqueous mistletoe extract](#). *Eur J Med Res* 9(6):316-22
11. Adler M, Langer M, Witthohn K, Eck J, Blohm D, Niemeyer CM (2003) Detection of rViscumin in plasma samples by immuno-PCR.; *Biochem Biophys Res Comm* 300: 757 – 763
12. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C (2004) Phase I Trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research of Cancer New Drug Development Group. *Ann Oncol* 15:1816 – 1824
13. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. *Clin Cancer Res* 10(11):3699-3707
14. [Samtleben R, Kiefer M, Luther P \(1985\) Characterization of the different lectins from \*Viscum album\* L. \(mistletoe\) and their structural relationships with the agglutinins from \*Abrus precaratorius\* and \*Ricinus communis\*. In: Kocourek J, Freed DLJ \(eds\) \*Lectins: Biology, Biochemistry, Clinical Biochemistry\* Vol. 4, Sigma Chemical Company, St. Louis, Missouri, USA, pp 617–626](#)
15. [Franz M, Vollmer S, Wacker R, Jäger S, Scheer R, Stoeva S, Lehmann R, Tsitsilonis R, Voelter W \(2005\) Isolation and quantification of the chitin-binding mistletoe lectins](#)

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- [\(cbMLs\) from mistletoe extracts and the validation of this method. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H \(eds\) Fortschritte in der Misteltherapie, KVC Verlag, pp 69-81](#)
16. Adler, M., Wacker, R, Niemeyer, CM (2008) Sensitivity by combination: immuno-PCR and related technologies. *Analyst* 133(6):702-718
17. Eck J, Langer M, Möckel B, Witthohn K, Zinke H, Lentzen H (1999) Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. *Eur J Biochem* 265(2):788-797
18. Elsässer-Beile U, Voss M, Schühle R, Wetterauer U (2000) Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. *J Clin Lab Anal* 14(6):255-259
19. ADVINUS Therapeutics Private Limited (2009) Mistletoe extract AbnobaViscum Fraxini 20mg: 90 day study in Sprague-Dawley rats by subcutaneous route with toxicokinetics and 4 week recovery period. ADVINUS report-No. G5087-90R-SC, Bangalore, India
20. [Klein R, Classen K, Berg PA, Lüdtke R, Werner M, Huber R \(2002\) In vivo-induction of antibodies to mistletoe lectin-I and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. \*Eur J Med Res\* 7\(4\):155-163.](#)
21. [Jacobs CA, Lynch DH, Roux ER, Miller R, Davis B, Widmer MB, Wignall J, VandenBos T, Park LS, Beckmann MP \(1991\) Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. \*Blood\*. 77\(11\):2396-2403.](#)
22. [Hayashi N, Kinoshita H, Yukawa E, Higuchi S \(1998\) Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. \*Br J Clin Pharmacol\*. 46\(1\):11-9.](#)
23. Mabed M, El-Helw L, Shamaa S (2004) Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. *Br J Cancer* 90(1):65-69



Table 1: Volunteer demographics

	Demographic characteristics (n=15)						
	Arithmetic mean	SD	Minimum	Median	Maximum	95% Confidence Interval	
						Lower limit	Upper limit
Age [years]	31.4	6.3	18.0	30.0	42.0	18.0	42.0
Height [cm]	181.3	6.4	171.0	180.0	193.0	171.0	193.0
Weight [kg]	78.0	10.4	65.0	74.0	99.0	65.0	99.0
BMI [kg/m <sup>2</sup> ]	23.7	2.4	20.3	23.5	27.7	20.3	27.7

For Peer Review

**Table 2:** Summary of the pharmacokinetic parameters of natural mistletoe lectins

Pharmacokinetic parameters of <u>natural</u> mistletoe lectins after one single subcutaneous dose of abnovaVISCUM® Fraxini 20 mg										
	n	Mini- mum	Maxi- mum	Arith- metic Mean	Standard Deviation	Lower Quar- tile	Medi- an	Upper Quar- tile	Lower Limit 95% CI	Upper Limit 95% CI
$C_{max}$ [pg/ml]	15	188,7	3738	1043	1162	283	594	1029	189	3738
$t_{max}$ [h]	15	0,3	336,0	26,4	85,8	1,0	2,0	10,0	0,3	336
AUC(0- tlast) [h*pg/ml]	15	1401	125405	34652	35786	4533	20984	58116	1401	125405
AUC(0-∞)* [h*pg/ml]	7	1401	20984	8395	8173	2552	4533	19084	1401	20984
CLsc(0- 72h)** [L/h]	15	428	14279	3819	3543	1510	2739	4589	428	14279
CLsc(0- 336h)** [L/h]	15	160	14279	2779	4001	344	953	4412	160	14279
CLsc(0-∞)* [L/h]	7	953	14279	5412	4701	1048	4412	7837	953	14279

Maximum plasma-concentration  $C_{max}$

Time to reach maximum plasma-concentration  $t_{max}$  [h] and Elimination rate constant  $\lambda_z$  [1/h]: could not be determined in any of the volunteers due to non-linear course of the concentration-time profiles.

Area under the plasma-concentration-time-curve AUC(tlast-∞): could not be determined, since extrapolation of the concentration-time-curves from last datapoint to infinite time was not possible in volunteers No. 2,3, 9-13 and 15 due to non-linear run of the curves and was not necessary in volunteers No. 1, 4-8 and 14 because mistletoe lectin serum concentrations had already decreased to or below predose values within the time period of blood sampling, i.e. within the timepoint of last blood sampling (tlast).

\*AUC(0-∞) and apparent subcutaneous clearance CLsc(0-∞): The summary statistics for AUC(0-∞) and CLsc(0-∞) included only n=7 volunteers, i.e. volunteers No. 1, 4-8 and 14 in whom the total AUC was equal to the AUC(tlast-∞). Volunteers No. 2,3, 9-13 and 15 could not be taken into account for the summary statistics of AUC(0-∞) and CLsc(0-∞), because in these cases AUC(tlast-∞) could not be determined (see above).

\*\*CLsc(0-72h) and CLsc(0-336h): Because the apparent subcutaneous clearance CLsc (CLsc(0-∞)) could not be determined in most of the volunteers, the apparent subcutaneous clearances for the time periods from 0 to 72 hours (CLsc(0-72h)) and from 0 to 336 hours (CLsc(0-336h)) were determined in all volunteers.

Table 3: Individual pharmacokinetic parameters of natural mistletoe lectins

Pharmacokinetic parameters										
	$C_{max}$ [pg/ml]	$t_{max}$ [h]	$\lambda_z$ [1/h]	$t_{1/2}$ [h]	AUC (0- $t_{last}$ ) [h*pg/ml]	AUC ( $t_{last}$ - $\infty$ ) [h*pg/ml]	AUC (0- $\infty$ ) [h*pg/ml]	CL <sub>sc</sub> (0-72h) [L/h]	CL <sub>sc</sub> (0-336h) [L/h]	CL <sub>sc</sub> (0- $\infty$ ) [L/h]
Volunteer 1	715	1,0	*	*	19083	#	19083	3084	1048	1048
Volunteer 2	2970	0,7	*	*	125405	*	*	428	159	*
Volunteer 3	3738	1,0	*	*	30141	*	*	1719	663	*
Volunteer 4	2916,	1,0	*	*	3049	#	3049	6559	6559	6559
Volunteer 5	593	18,0	*	*	7161	#	7161	2792	2792	2792
Volunteer 6	660	1,0	*	*	20984	#	20984	2739	953	953
Volunteer 7	1028	2,0	*	*	4533	#	4533	4411	4411	4411
Volunteer 8	959	2,0	*	*	2552	#	2552	7836	7836	7836
Volunteer 9	368	10,0	*	*	66726	*	*	1510	299	*
Volunteer 10	447	2,0	*	*	58115	*	*	890	344	*
Volunteer 11	307	336,0	*	*	85601	*	*	1429	233,	*
Volunteer 12	188	0,3	*	*	39024	*	*	2585	512	*
Volunteer 13	283	12,0	*	*	18971	*	*	4588	1054	*
Volunteer 14	222	1,5	*	*	1400	#	1400	14279	14279	14279
Volunteer 15	250	8,0	*	*	37028	*	*	2432	540	*

\*no determination possible due to non-linear run of curve; # no extrapolation necessary since serum concentration decreased to or below predose values within the time period of blood sampling

**Table 4: Safety laboratory parameters: Difference from before to 14 ± 3 days after subcutaneous application of 1ml abnovaVISCUM® Fraxini 20mg (n=15)**

Parameter	Lower Quartile	Median	Upper Quartile	Lower Limit 95% CI	Upper Limit 95% CI
Hemoglobin (g/dl)	-0.9	-0.2	0	-1.5	1.4
White blood count / $\mu$ l	70	640	1220	-990	2680
Platelet count / $\mu$ l	58000	108000	136000	3000	18000
Creatinine (mg/dl)	0	0	0.1	-0.1	0.3
Uric acid (mg/dl)	-0.3	0.3	0.9	-1.0	1.2
Sodium (mmol/l)	-1	1	2	-5	3
Potassium (mmol/l)	0.1	0.3	0.7	-0.3	1.2
Calcium (mmol/l)	0	0.1	0.2	0	0.3
Creatinkinase (U/l)	-39	1	19	-80	119
Alanine aminotransferase (U/l)	1	5	20	-5	31
Aspartate aminotransferase (U/l)	-1	2	4	-6	11
Lactate dehydrogenase (U/l)	11	22	27	-10	48
Gamma glutamyltransferase (U/l)	0	3	8	-2	30
Bilirubin (mg/dl)	-0.3	-0.1	0	-1.3	0.4
Alpha amylase (mg/dl)	-2	4	11	-5	25
Total protein (g/dl)	0	0.5	0.8	-0.4	1.2
Albumin (g/dl)	-0.1	0.4	0.6	-0.4	0.9
C-reactive protein (mg/dl)	0	0.2	0.5	0	0.7
Cholesterol (mg/dl)	-7	2	14	-35	32
Triglycerides (mg/dl)	-19	5	52	-62	103
Glucose (mg/dl)	-3	-1	4	-4	21




Figure 1: Individual **natural mistletoe lectin** concentration-time profiles (n=15)




Figure 1a: Individual natural mistletoe lectin concentration-time profiles (n=15)

Formatted: Highlight  
 Deleted: M  
 Formatted: Highlight




Figure 1b: Arithmetic Mean (+ standard deviation) of natural mistletoe lectin concentration-time profiles (n=15)

Formatted: Highlight  
Deleted: M  
Formatted: Highlight




Figure 2: Arithmetic mean of sublingual body temperature after (n=15)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Pharmacokinetics of natural mistletoe lectins after subcutaneous injection

Roman Huber<sup>1</sup>, Jürgen Eisenbraun<sup>2</sup>, Barbara Miletzki<sup>3</sup>, Michael Adler<sup>4</sup>, Rainer Scheer<sup>2</sup>, Reinhild Klein<sup>5</sup>, Christoph H. Gleiter<sup>3</sup>

<sup>1</sup> Department of Environmental Health Sciences, University Hospital Freiburg, Germany

<sup>2</sup> Abnoba GmbH, Pforzheim, Germany

<sup>3</sup> CenTrial GmbH, Tübingen/Ulm, Germany

<sup>4</sup> Chimera Biotec GmbH, Dortmund, Germany

<sup>5</sup> Department of Internal Medicine II, University of Tübingen, Germany

Corresponding author

Dr. Roman Huber

Department of Environmental Health Sciences

University Hospital Freiburg

Breisacher Str. 115b

D-79106 Freiburg

Germany

Phone: 0049 761 270 8201

Fax: 0049 761 270 8323

Email: roman.huber@uniklinik-freiburg.de

## Abstract

**Purpose:** Knowledge of natural mistletoe lectins (nML) pharmacokinetics can be regarded as essential for further rational studies with mistletoe preparations. Studies with intravenous application of a recombinant type II ribosome inactivating protein (rML) analogous to nML revealed a short half life of about 13 minutes in cancer patients. This open-label, phase I, monocenter clinical trial was performed in order to describe the pharmacokinetics of nML.

**Methods:** In 15 healthy male volunteers aged 18-42 years nML were detected with a modified sandwich Immuno-PCR technique (Imperacer®, Chimera Biotec) after single subcutaneous injection of a mistletoe extract (abnobaVISCUM® Fraxini 20mg) with marketing authorisation, containing about 20µg nML per millilitre. Secondary objectives were safety and the number of activated natural killer cells (CD54+/CD94+). **Results:** In none of the volunteers nML were detectable before the injection and in all volunteers nML were detected in serum samples after the injection. Individual variability however was large. The mean and median peak concentration was reached 1 and 2 hours after injection, respectively. In some of the volunteers nML were still detectable at the final investigation 2 weeks after injection. The injection resulted in fever and flue like symptoms in all volunteers but no serious adverse events occurred. All symptoms and local reactions at the injection site completely disappeared within a range of 4 to 95 days. The number of activated natural killer cells did not change. **Conclusions:** nML from abnobaVISCUM® Fraxini 20mg are detectable in serum after a single subcutaneous injection. Detectability is considerably longer compared to intravenous. rML. The subcutaneous injection of this preparation without usual pre-treatment with lower doses results in short-lasting fever and other flu-like symptoms.

## Key words:

abnobaVISCUM, anthroposophical medicine, healthy volunteers, phytotherapy, safety, NK-cells

## Introduction

Mistletoe preparations are used since decades for supportive cancer treatment within the concept of anthroposophical medicine. Despite more than 40 randomized clinical trials, the efficacy of mistletoe treatment in cancer therapy is yet not clear and discussed controversially [1]. Reasons for this unsatisfactory situation are, that different mistletoe preparations with different ingredients in different concentrations have been tested and that the pharmacology of mistletoe extracts is unclear. Active ingredients of mistletoe extracts are mainly mistletoe lectins (nML), viscotoxins and polysaccharides. From these, nML are the most interesting substances for anticancer activity. They have in in-vitro and animal models been demonstrated to have distinct cytotoxic properties [2, 3]. In doses below cytotoxicity nML stimulate the unspecific and specific immune system in humans [4].

ML are glycoproteins and occur naturally in 2 types, the ribosome inactivating proteins of class 2, which are divided in the 3 subtypes nML-I, -II and -III and viscum album chitin-binding ML (cbML). The molecular weight of nML I-III is about .63 kDa. They have very similar biological properties and are composed of a N-glycosidase (A-chain) and a galactoside-recognizing lectin (B-chain), connected by a disulfide bridge [5, 6]. The A-chain inhibits protein synthesis [7, 8]. The B-chain binds to carbohydrate residues on the cell surface, thus entering the cell by receptor-mediated endocytosis and inducing apoptosis of the cell [8, 9]. The cbML belongs to a different class of lectins with a different structure, low antigenicity and a molecular weight of only about 11 kDa [10]. It is far less toxic than nML I-III and is not included in our analysis.

Recently, the technique to detect nML I-III in nanogram ranges in human serum has been developed [11, 12]. A recombinant type II ribosome inactivating protein (rML) analogous to natural mistletoe lectin I revealed a short half life of about 13 minutes in cancer patients [12]. Knowledge of nML pharmacokinetics can be regarded as important to optimize clinical use and further rational studies with mistletoe preparations. To the first time, we therefore investigated the pharmacokinetics of natural mistletoe lectin from a commercially available mistletoe preparation in humans.

## Patients and Methods

The study was performed as an uncontrolled, non-randomized, open-label, phase I, mono-center clinical trial. Primary outcome was the pharmacokinetics of nML following a single dose (1 ml) of subcutaneously administered abnobaVISCUM<sup>®</sup> Fraxini 20mg in healthy male volunteers. Secondary outcomes were safety and activation markers (CD54+/CD94+) on natural killer (NK) cells. This marker was selected, because treatment of patients with metastatic colorectal cancer and lung cancer with NK-cells (CD54+/CD94+) activated by heat shock proteins showed promising anti-tumor effects [13]. We wanted to test the hypothesis, that mistletoe-induced fever activates NK-cells.

The study comprised a screening (examination 1), a period of hospitalisation (examination 2 to 6) from the night before until 72 hours after s.c. injection of the IMP (investigational medicinal product) and a final follow-up (examination 7) on day 14 +/- 3 after injection of the IMP. nML-concentrations in volunteers' sera were analysed before and 0.3, 0.7, 1.0, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48, 72 and 336 hours after injection of the IMP. Safety laboratory parameters (creatinine, urea, uric acid, sodium, potassium, chloride, calcium, creatine kinase, alanin amino transferase (ALT), aspartate amino transferase (AST), lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl-transferase, total bilirubin, total protein, albumin, alpha-amylase, C-reactive protein (CRP), cholesterol, triglycerides, glucose) were determined at examinations 1, 2, and 7. CD54+/CD94+ NK cells were determined before and 6, 24 and 72 hours after injection of the IMP.

Inclusion criteria were: 18-45 years old non smoking healthy males, body mass index 18.5-28 kg/m<sup>2</sup> with normal values for blood pressure, pulse rate, body temperature, normal haematological, biochemical and coagulation parameters and normal electrocardiogram. Exclusion criteria were signs of any clinically significant disease, regular use of medication, drug abuse, positive urine screening for drugs, positive blood test for ethanol, participation in another clinical trial, previous therapy with mistletoe preparations, history of allergy to a medicinal product, allergic diseases except the investigator considered them as clinically irrelevant for the purpose of this clinical trial, positive HIV, hepatitis B or C serology, regular intake of more than 20g ethanol per day, donation of blood within 3 months prior to study entry, difficult peripheral venous access and inability to understand the nature and the extent of the trial.

1  
2  
3 Only volunteers who gave written informed consent and met all eligibility criteria were  
4 included into the study.  
5

6  
7 The relevant ethics committee had provided a favourable opinion on the clinical trial prior to  
8 study start and the study was performed in compliance with the principles of Good Clinical  
9 Practice and the Declaration of Helsinki.  
10  
11

### 12 13 14 Medication

15 AbnobaVISCUM<sup>®</sup> Fraxini 20mg is an injectable, endotoxin free plant extract from the  
16 European mistletoe species *Viscum album* L. for the treatment of malignant tumors, tumor  
17 recurrences and defined precanceroses. As abnobaVISCUM<sup>®</sup> Fraxini 20 mg has the highest  
18 content of nML (approx. 20.000ng/ml) of all commercially available mistletoe preparations,  
19 this preparation was chosen in order to detect nML in the nanogram range after subcutaneous  
20 injection. Mistletoes from deciduous trees like the ash tree, from which abnobaVISCUM<sup>®</sup>  
21 Fraxini is derived, have relatively high proportions of nML I in relation to nML II/III [14] but  
22 due to methodological difficulties, no differentiation of the MLs could be performed in the  
23 commercial extract. The amount of cbML in abnobaVISCUM<sup>®</sup> Fraxini 20 mg has been about  
24 1µg/ml [15]. Each volunteer was given the same single dose (1 ml) of subcutaneously  
25 administered abnobaVISCUM<sup>®</sup> Fraxini 20mg. No dose adjustments were necessary, since the  
26 inclusion criteria limited the body mass index of the volunteers to a range of 18.5-28 kg/m<sup>2</sup>.  
27 Intratumoral injections with abnobaVISCUM<sup>®</sup> Fraxini 20 mg resulted in highly significant  
28 tumor reductions in human pancreatic cancer xenografts [3].  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 Quantification of nML and activated NK-cells

44 Each blood sample was put on ice immediately after collection and centrifuged for 10 minutes  
45 at 4°C and 2500xg. Thereafter, at least 2 ml of serum were immediately frozen and stored at  
46 -80°C in the clinical trial center.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 nML in the sera of the volunteers was measured by an ultrasensitive immuno-PCR method  
4 (Imperacer<sup>®</sup>) [11, 12, 16], which combines protein detection through ELISA with the  
5 exponential signal amplification typical for PCR. The method was validated by Chimera  
6 Biotech GmbH, Dortmund, Germany for natural mistletoe lectins of abnobaVISCUM<sup>®</sup> in  
7 human serum. It does not discriminate between the nML subtypes I-III. Due to the completely  
8 different structure it does not detect cbML. Briefly, the antigen was immobilized on capture-  
9 antibody coated microplate surfaces directly from the serum samples as delivered for analysis  
10 without additional purification. For minimization of background effects, the samples were  
11 diluted 1:3 in a detergent-containing sample dilution buffer. Parallel to the samples, a dilution  
12 series of the antigen was studied, abnobaVISCUM<sup>®</sup> Fraxini 20 mg, batch no. 407B04 and  
13 abnobaVISCUM<sup>®</sup> Mali 20 mg, batch no. 502B33 (both ABNOBA GmbH, Germany) were  
14 used as reference substance. Spiked samples were used as a calibration curve for  
15 quantification of the antigen and testing robustness and specificity. Each calibration curve  
16 (6000 – 93.75 pg/ml antigen) was prepared in antigen-free individual serum, taken previous to  
17 the application of the antigen. This dilution series was additionally frozen to simulate the  
18 effect of freezing on the antigen-containing samples for analysis. Following incubation of the  
19 samples and the calibration curve, the immobilized antigen was coupled with a specific  
20 antibody-DNA conjugate. The assay was carried out with a lectin-specific tailored Imperacer<sup>®</sup>  
21 Kit (No. 11-030, Chimera Biotec, Germany). Monoclonal mouse-anti-ML antibody 5F5, anti-  
22 ML-I-(A-Chain) and 5H8 Anti-ML-A (Institut für Immunopräparate und Nährmedien GmbH,  
23 , Germany) were used as detection- and capture antibody, respectively.

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 After a washing step the DNA-marker was amplified by real-time PCR. In data analysis, a  
42 baseline correction was applied. The instrument software calculates the threshold cycle (Ct),  
43 which represents the first PCR cycle at which the reporter signal exceeds the signal of the  
44 baseline (“threshold”), and sets it in the phase where the signal increases linearly. Baseline  
45 correction and threshold were identical in all validation measurements.  $\Delta$ Ct values were  
46 calculated by subtracting the Ct values obtained for each signal from the total number of  
47 cycles carried out in the experiment. This purely mathematical conversion facilitates the  
48 comparison of the data with conventional ELISA data as  $\Delta$ Ct values are directly proportional  
49 to the antigen concentration.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Assay precision, sensitivity, specificity and robustness were suitable for this pharmacokinetic  
4 study. A linear concentration range of the Imperacer<sup>®</sup> assay was validated from 0.1-100 ng  
5 nML/ml. Regarding a dose of 20.000 ng nML and approximately 3000 ml serum in humans a  
6 maximum concentration of 6.6 ng nML/ml was expected to be measured, if 100% of injected  
7 nML would have been distributed equally and immediately in the blood circulation without  
8 metabolism. With a linear measurement range starting at 0.1 ng it was possible to measure  
9 a quantitative nML concentration if only 5 % of the injected amount of 1 ml  
10 abnobaVISCUM<sup>®</sup> Fraxini 20 mg appeared in the blood circulation at one sample timepoint.  
11 This was expected to be low enough for a successful detection of the kinetic parameters. 0.1  
12 ng nML/ml was the cut off value, from which on nML concentrations were positive.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 For the determination of NK cells, heparinized blood was used, and peripheral blood  
24 mononuclear cells (PBMC) were isolated by Ficoll-gradient. After staining with PE-  
25 conjugated anti-CD56, PerCP-conjugated anti-CD45 and FITC conjugated anti-CD94  
26 antibodies (all obtained from Becton-Dickinson [San Jose, CA]) the PBMC were incubated  
27 with the respective antibodies or IgG isotype control antibodies (BD Biosciences  
28 Pharmingen). A minimum of 10 000 lymphocytes were counted. Quadrants were set based  
29 upon the isotype controls for each antibody.  
30  
31  
32  
33  
34  
35  
36

### 37 Statistics

38 No comparison with a control group was planned and no data for comparison did exist. Since  
39 the study was to be conducted for exploratory purposes no statistically based sample size  
40 calculation was performed. It was planned to include n=16 (two groups of n=8) healthy male  
41 volunteers into the trial, because this is a sufficient number to enable evaluation of the single  
42 dose-pharmacokinetics of abnobaVISCUM<sup>®</sup> Fraxini 20mg.  
43  
44  
45  
46  
47

48 For statistical analyses two populations of clinical trial participants were defined:

- 49 1) The pharmacokinetic population which had to include all clinical trial participants who  
50 provided evaluable and interpretable pharmacokinetic results during the 72 hrs after dosing of  
51 abnobaVISCUM<sup>®</sup> Fraxini 20mg.  
52
- 53 2) The safety population which had to encompass all clinical trial participants who met all  
54 eligibility criteria and were included in the clinical trial.  
55  
56  
57  
58  
59  
60

1  
2  
3 The analyses of the nML-pharmacokinetics and the immunological activation marker had to  
4 be performed on the pharmacokinetic population. The evaluation of safety and tolerability had  
5 to be performed on the safety population. Missing or manipulated data had to be corrected if  
6 possible. If this was not possible the data were to be treated as missing data.  
7  
8  
9

## 10 11 12 Results

13  
14  
15 N=35 volunteers were screened and n=20 were found to be eligible for the study. Deviating  
16 from the originally planned sample size of n=16, only n=15 were administered the IMP. 5 had  
17 to be excluded before IMP administration due to newly developed exclusion criteria between  
18 screening and hospitalisation. Demographics of the volunteers are shown in table 1. nML  
19 were detectable in none of the volunteers before and in all volunteers after injection of the  
20 IMP. Although all volunteers received the s.c. injection of the IMP from the same  
21 experienced investigator, individual serum concentration-time profiles varied considerably:  
22 Volunteers No 1 to 9 and 14 (10/15 volunteers (67%) showed a fast increase with high  
23 concentrations of nML followed by a slow decrease. A second increase was observed in  
24 volunteers No 2, 5, 9 and 14 (4/15, 27%). The remaining 5/15 volunteers (33%), i.e. volunteers  
25 No 10 to 13 and 15, had an undulating course with low levels of nML-concentrations. At the  
26 final examination (day 14 +/- 3 days after injection) serum nML-concentrations were not  
27 detectable in 5/15 volunteers but 9/15 volunteers (60%) had still measurable nML-  
28 concentrations. For one volunteer the last scheduled nML-concentration could not be  
29 determined because he did not appear to the last examination. The course of nML-  
30 concentrations is shown in Figure 1, the pharmacokinetic data are presented in Table 2 and 3.  
31 The mean serum peak concentration was observed at 01:00 hour post-dose. By the end of the  
32 study the curve had not yet, but almost returned to pre-dose values.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The arithmetic means of  $C_{\max}$  and  $AUC(0-\infty)$  amounted to 1043pg/ml and 8395 h\*pg/ml,  
4 respectively.  $t_{\max}$  ranged from 0.3 to 336.0 hours with a median of 2.0 hours. A calculated  
5 concentration of 3.7 ng nML/ml for the highest signal of the study as determined in volunteer  
6 No 3, 1h after injection corresponds to 56% serum-availability for this time point (100% = 6.6  
7 ng/ml). Calculation of  $\lambda_z$  and  $t_{1/2}$  ( $t_{1/2} = \ln 2 / \lambda_z$ ) was in none of the volunteers possible due to  
8 non-linear concentration-time profiles. The  $AUC(0-t_{\text{last}})$  was determined by trapezoidal  
9 analysis. In volunteers No. 2, 3, 9 -13 and 15,  $AUC(t_{\text{last}}-\infty)$  could not be determined because  
10 the nML-concentration-time curves could not be extrapolated to  $\infty$  due to non-linearity. In  
11 volunteers No. 1, 4 to 8 and 14,  $AUC(t_{\text{last}}-\infty)$  did not need to be determined because nML-  
12 concentrations decreased below detection threshold within the time period of blood sampling.  
13 For volunteers in whom the nML serum concentrations had not decreased below detection  
14 threshold of 100pg/ml in the time period of blood sampling, i.e. for 10/15 volunteers (67%),  
15  $AUC(0-\infty)$  and  $CL_{\text{sc}}(0-\infty)$  were not determinable.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Compared to baseline, activated NK-cells (CD54+/CD94+) as proportion of total NK-cells  
29 (CD16+/CD56+) did not significantly change after injection of the IMP.  
30  
31  
32

33 There were no serious adverse events whether drug-related or not. 53/55 treatment emergent  
34 AEs were assessed by the investigator to be at least possibly related to the IMP and all 15  
35 volunteers experienced one or more AE with at least possible causal relationship to the IMP.  
36 Only 3/55 treatment emergent AEs observed in 2/15 volunteers (13 %) were of severe  
37 intensity (flue-like symptoms in 2, nausea in 1 volunteer).  
38  
39  
40  
41  
42

43 As expected, a local inflammatory reaction at the injection site of abnobaVISCUM<sup>®</sup> Fraxini  
44 20mg was observed in almost all study participants (14/15 volunteers, 93%) and 15/15  
45 volunteers had an increase of body temperature to  $>37.5^{\circ}\text{C}$  (Figure 2) which was  
46 accompanied by flu like symptoms in all and nausea in 8 volunteers. 11/15 volunteers (73.5  
47 %) took concomitant medication because of pain at the injection site during hospitalisation  
48 and 3/15 volunteers also after discharge from the clinical trial center. In 12/15 volunteers (80  
49 %) the inflammatory reaction persisted beyond the final study examination the longest  
50 duration of the reaction amounting to 95 days.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 With regard to laboratory evaluations, no clinically significant deviations of haematological,  
4 biochemical and urinalysis parameters from the normal range were observed at the final  
5 examination (day 14+/-3 days) after administration of the IMP (Table 4). None of the  
6 volunteers showed a clinically significant abnormality in the ECG throughout the study. Apart  
7 from the above described local inflammatory reactions at the injection site no clinically  
8 significant abnormalities were found during the physical examination.  
9  
10  
11  
12  
13

## 14 Discussion

15  
16  
17  
18  
19 This study investigated for the first time pharmacokinetics of naturally occurring mistletoe  
20 lectins from a commercially available nML-rich mistletoe extract. The main findings were:  
21  
22

- 23 1. nML from mistletoe extracts can be detected in the human serum after a single  
24 subcutaneous injection.
- 25 2. Detectability of nML in serum is considerably longer than that of recombinant type II  
26 ribosome inactivating protein (rML) analogous to mistletoe lectin.
- 27 3. Pharmacokinetics of nML after subcutaneous injection is subject to considerable inter-  
28 individual variability.  
29  
30  
31  
32  
33  
34  
35

36  
37 Due to non-linear kinetics the half-life of nML could not be determined, since calculation of  
38 half-life is meaningless in case of non-linear concentration-time-profiles. Because half-life of  
39 rML is only 13 minutes [12] and in 9/15 of our volunteers nML was detectable even two  
40 weeks after injection, a longer detectability of nML in serum can be concluded, even though  
41 the route of application was intravenous in the study of Schöffski et al. and subcutaneous in  
42 our study. In contrast to rML, nML is glycosylated and has different kinetics of association  
43 and dissociation with glycoconjugates. Furthermore, B-chains of rML and nML differ in  
44 binding specificity to carbohydrates [17]. This may cause different uptake and distribution in  
45 blood and tissue and could explain the longer detectability of nML in serum. Cytotoxicity of  
46 nML and rML were similar in MOLT-4 cell cultures [17]. In vitro studies using human  
47 peripheral blood mononuclear cells, however, significant differences of rML and nML on cell  
48 viability and immunomodulation were found [18].  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 A long detectability in serum regarded as advantageous for therapeutic use might be opposed  
59 by the strong interindividual differences of nML pharmacokinetics after subcutaneous  
60 injection.

1  
2  
3 The high interindividual differences that were observed although all volunteers were injected  
4 by the same investigator in the same abdominal quadrant may be attributed to different  
5 patterns of nML binding to carbohydrates and release from the subcutaneous tissue. The  
6 observed non-linear pharmacokinetics of the large nML molecules (50-63kDa) would support  
7 this hypothesis. Pharmacokinetic investigations in rats, performed within a subchronic  
8 toxicity study with abnobaVISCUM<sup>®</sup> Fraxini 20mg also showed high interindividual  
9 differences between the animals under GLP-conditions [19]. Cross-reactivities could  
10 potentially have affected the test results but are unlikely. Cross-reactivity to cbML can be  
11 excluded because of its completely different structure and because comparing experiments  
12 with antibodies to nML I-III and cbML in healthy volunteers and tumor patients did not show  
13 cross-reactivity [10]. Because nML I-III is highly antigenic after parenteral injection (almost  
14 100% of nML exposed individuals develop anti-nML antibodies) and anti-nML antibodies are  
15 absent in individuals without previous exposure to parenteral mistletoe preparations [20], a  
16 cross reactivity to environmental factors like diet or inhalative environmental antigens can  
17 also widely be excluded. Metabolites of nML are, to our knowledge, not known.

18  
19 We choose the subcutaneous application, because this is the common form for mistletoe  
20 preparations and abnobaVISCUM<sup>®</sup> Fraxini 20mg has only the marketing authorisation for  
21 subcutaneous injection. Also pharmacokinetics of other molecules, like soluble, recombinant  
22 interleukin-4 receptor (sIL-4R)[21] and erythropoietin [22], with a size comparable to nML of  
23 140- and 34 kDa, respectively, were investigated after subcutaneous (s.c.) injection. Murine  
24 sIL-4R elimination half life was 2.3 hours following intravenous injection and 6.2 hours after  
25 s.c. injection. Also the sIL-4R blood level was lower after s.c. injection but bioavailability  
26 was comparable. Subcutaneously applied erythropoietin, given to 48 volunteers, resulted in  
27 considerable inter-individual differences of  $C_{max}$  from 40 to 95 IU/l. The half life was about 3  
28 times longer than after intravenous application. Despite the comparability with these  
29 endogenously occurring substances is limited, the findings of a longer detectability and higher  
30 inter-individual differences are in principle in accordance with our results.

31  
32 Initial high doses of subcutaneously applied abnobaVISCUM<sup>®</sup> Fraxini 20 mg have a variety  
33 of side effects, especially fever and related symptoms and strong local reactions. The  
34 manufacturer recommends, therefore, lower doses for initial therapy. In one publication,  
35 however, even higher doses (2 ampoules abnobaVISCUM<sup>®</sup> Fraxini 20mg) were applied  
36 initially and had beneficial effects in 23 patients with advanced hepatocellular carcinoma [23].  
37 The non-hematological toxicity included fever, erythema and pain at the injection site as in  
38 our volunteers. No hematological toxicity was observed. This published clinical experience  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 encouraged us to regard 1 ampoule abnobaVISCUM<sup>®</sup> Fraxini 20 mg as safe for this phase I  
4 pharmacokinetic study. The hypothesis, that the percentage of activated NK-cells  
5 (CD54+/CD94+) increases after a single injection of abnobaVISCUM<sup>®</sup> Fraxini 20mg could  
6 not be confirmed.  
7  
8  
9

10 Since it is now known that natural mistletoe lectins are absorbed into the blood after  
11 subcutaneous injection of abnobaVISCUM<sup>®</sup> Fraxini 20mg in healthy volunteers,  
12 pharmacokinetic considerations should also be addressed in subsequent clinical trials with  
13 mistletoe preparations for oncological patients.  
14  
15  
16  
17

#### 18 Acknowledgment

19 The study was sponsored by Abnoba GmbH, Pforzheim, Germany.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

#### 30 References

- 31  
32  
33  
34 1. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in  
35 oncology. *Cochrane Database Syst Rev* (2):CD003297  
36  
37 2. Ribéreau-Gayon G, Jung ML, Frantz M, Anton R (1997) Modulation of cytotoxicity  
38 and enhancement of cytokine release induced by *Viscum album* L. extracts or  
39 mistletoe lectins. *Anticancer Drugs* 8 Suppl 1:S3-8  
40  
41 3. Rostock M, Huber R, Greiner T, Fritz P, Scheer R, Schueler J, Fiebig HH (2005)  
42 Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into  
43 human pancreatic cancer xenografts. *Anticancer Res* 25(3B):1969-1975  
44  
45 4. Huber R, Rostock M, Goedl R, Lüdtke R, Urech K, Buck S, Klein R (2005) Mistletoe  
46 treatment induces GM-CSF- and IL-5 production by PBMC and increases blood  
47 granulocyte- and eosinophil counts: a placebo controlled randomized study in  
48 healthy subjects. *Eur J Med Res* 10(10):411-418  
49  
50 5. Franz H (1985) Inhaltsstoffe der Mistel (*Viscum album* L.) als potentielle Arzneimittel.  
51 *Pharmazie* 40:97-104  
52  
53 6. Franz H (1991) Mistletoe lectins (2). In: Franz, H (ed) *Advances in Lectin Research*,  
54 Springer Berlin, pp 33-50  
55  
56  
57  
58  
59  
60

- 1  
2  
3 7. Franz H, Friemel H, Buchwald S, Plantikow A, Kopp J, Körner I.J (1990) The A chain  
4 of lectin 1 from European mistletoe (*Viscum album*) induces interleukin-I and  
5 interleukin-II in human mononuclear cells. In: Kocourek J, Freed DLJ (eds) *Lectins:*  
6 *Biology, Biochemistry, Clinical Biochemistry* Vol. 7, Sigma Chemical Company, St.  
7 Louis, Missouri, USA, pp. 247-250
- 8  
9  
10  
11  
12 8. Stirpe F, Barbieri L, Batteli MG, Soria M, Lappi DA (1992) Ribosome-inactivating  
13 proteins from plants: present status and future prospects. *Bio Technology* 10:405-412
- 14  
15  
16  
17 9. Büssing, A (2000) Biological and pharmacological properties of *Viscum album* L. In:  
18 Büssing, A (ed) *Mistletoe, the Genus Viscum*. Amsterdam (2000)
- 19  
20  
21 10. Klein R, Franz M, Wacker R, Classen K, Scheer R, Von Laue HB, Stoeva S, Voelter  
22 W (2004) Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in  
23 tumor patients before and during therapy with an aqueous mistletoe extract. *Eur J Med*  
24 *Res* 9(6):316-22
- 25  
26  
27  
28 11. Adler M, Langer M, Witthohn K, Eck J, Blohm D, Niemeyer CM (2003) Detection of  
29 rViscumin in plasma samples by immuno-PCR.; *Biochem Biophys Res Comm* 300:  
30 757 – 763
- 31  
32  
33  
34 12. Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D,  
35 Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C  
36 (2004) Phase I Trial of intravenous aviscumine (rViscumin) in patients with solid  
37 tumors: a study of the European Organization for Research of Cancer New Drug  
38 Development Group. *Ann Oncol* 15:1816 – 1824
- 39  
40  
41  
42  
43 13. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K,  
44 Multhoff G (2004) Treatment of colon and lung cancer patients with ex vivo heat  
45 shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I  
46 trial. *Clin Cancer Res* 10(11):3699-3707
- 47  
48  
49  
50  
51 14. Samtleben R, Kiefer M, Luther P (1985) Characterization of the different lectins from  
52 *Viscum album* L. (mistletoe) and their structural relationships with the agglutinins  
53 from *Abrus precaratorius* and *Ricinus communis*. In: Kocourek J, Freed DLJ (eds)  
54 *Lectins: Biology, Biochemistry, Clinical Biochemistry* Vol. 4, Sigma Chemical  
55 Company, St. Louis, Missouri, USA, pp 617–626
- 56  
57  
58  
59  
60 15. Franz M, Vollmer S, Wacker R, Jäger S, Scheer R, Stoeva S, Lehmann R, Tsitsilonis  
R, Voelter W (2005) Isolation and quantification of the chitin-binding mistletoe lectins

- (cbMLs) from mistletoe extracts and the validation of this method. In: Scheer R, Bauer R, Becker H, Fintelmann V, Kemper FH, Schilcher H (eds) Fortschritte in der Misteltherapie, KVC Verlag, pp 69-81
16. Adler, M., Wacker, R, Niemeyer, CM (2008) Sensitivity by combination: immuno-PCR and related technologies. *Analyst* 133(6):702-718
17. Eck J, Langer M, Möckel B, Witthohn K, Zinke H, Lentzen H (1999) Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. *Eur J Biochem* 265(2):788-797
18. Elsässer-Beile U, Voss M, Schühle R, Wetterauer U (2000) Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. *J Clin Lab Anal* 14(6):255-259
19. ADVINUS Therapeutics Private Limited (2009) Mistletoe extract AbnobaViscum Fraxini 20mg: 90 day study in Sprague-Dawley rats by subcutaneous route with toxicokinetics and 4 week recovery period. ADVINUS report-No. G5087-90R-SC, Bangalore, India
20. Klein R, Classen K, Berg PA, Lüdtke R, Werner M, Huber R (2002) In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. *Eur J Med Res* 7(4):155-163.
21. Jacobs CA, Lynch DH, Roux ER, Miller R, Davis B, Widmer MB, Wignall J, VandenBos T, Park LS, Beckmann MP (1991) Characterization and pharmacokinetic parameters of recombinant soluble interleukin-4 receptor. *Blood*. 77(11):2396-2403.
22. Hayashi N, Kinoshita H, Yukawa E, Higuchi S (1998) Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. *Br J Clin Pharmacol*. 46(1):11-9.
23. Mabed M, El-Helw L, Shamaa S (2004) Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. *Br J Cancer* 90(1):65-69

**Table 1: Volunteer demographics**

	Demographic characteristics (n=15)						
	Arithmetic mean	SD	Minimum	Median	Maximum	95% Confidence Interval	
						Lower limit	Upper limit
Age [years]	31.4	6.3	18.0	30.0	42.0	18.0	42.0
Height [cm]	181.3	6.4	171.0	180.0	193.0	171.0	193.0
Weight [kg]	78.0	10.4	65.0	74.0	99.0	65.0	99.0
BMI [kg/m <sup>2</sup> ]	23.7	2.4	20.3	23.5	27.7	20.3	27.7

For Peer Review

**Table 2: Summary of the pharmacokinetic parameters of natural mistletoe lectins**

Pharmacokinetic parameters of natural mistletoe lectins after one single subcutaneous dose of abnoBaVISCUM® Fraxini 20 mg										
	n	Minimum	Maximum	Arithmetic Mean	Standard Deviation	Lower Quartile	Median	Upper Quartile	Lower Limit 95% CI	Upper Limit 95% CI
$C_{max}$ [pg/ml]	15	188,7	3738	1043	1162	283	594	1029	189	3738
$t_{max}$ [h]	15	0,3	336,0	26,4	85,8	1,0	2,0	10,0	0,3	336
AUC(0-tlast) [h*pg/ml]	15	1401	125405	34652	35786	4533	20984	58116	1401	125405
AUC(0-∞)* [h*pg/ml]	7	1401	20984	8395	8173	2552	4533	19084	1401	20984
CLsc(0-72h)** [L/h]	15	428	14279	3819	3543	1510	2739	4589	428	14279
CLsc(0-336h)** [L/h]	15	160	14279	2779	4001	344	953	4412	160	14279
CLsc(0-∞)* [L/h]	7	953	14279	5412	4701	1048	4412	7837	953	14279

Maximum plasma-concentration  $C_{max}$

Time to reach maximum plasma-concentration  $t_{max}$  [h] and Elimination rate constant  $\lambda_z$  [1/h]: could not be determined in any of the volunteers due to non-linear course of the concentration-time profiles.

Area under the plasma-concentration-time-curve AUC(tlast-∞): could not be determined, since extrapolation of the concentration-time-curves from last datapoint to infinite time was not possible in volunteers No. 2,3, 9-13 and 15 due to non-linear run of the curves and was not necessary in volunteers No. 1, 4-8 and 14 because mistletoe lectin serum concentrations had already decreased to or below pre-dose values within the time period of blood sampling, i.e. within the timepoint of last blood sampling (tlast).

\*AUC(0-∞) and apparent subcutaneous clearance CLsc(0-∞): The summary statistics for AUC(0-∞) and CLsc(0-∞) included only n=7 volunteers, i.e. volunteers No. 1, 4-8 and 14 in whom the total AUC was equal to the AUC(tlast-∞). Volunteers No. 2,3, 9-13 and 15 could not be taken into account for the summary statistics of AUC(0-∞) and CLsc(0-∞), because in these cases AUC(tlast-∞) could not be determined (see above).

\*\*CLsc(0-72h) and CLsc(0-336h): Because the apparent subcutaneous clearance CLsc (CLsc(0-∞)) could not be determined in most of the volunteers, the apparent subcutaneous clearances for the time periods from 0 to 72 hours (CLsc(0-72h)) and from 0 to 336 hours (CLsc(0-336h)) were determined in all volunteers.



Table 3: Individual pharmacokinetic parameters of natural mistletoe lectins

Pharmacokinetic parameters of natural mistletoe lectins after one single sc dose of abnobaVISCUM® Fraxini 20 mg										
Pharmacokinetic parameters										
$C_{max}$ [pg/ml]	$t_{max}$ [h]	$\lambda_z$ [1/h]	$t_{1/2}$ [h]	AUC (0- $t_{last}$ ) [h*pg/ml]	AUC ( $t_{last}$ - $\infty$ ) [h*pg/ml]	AUC (0- $\infty$ ) [h*pg/ml]	CL <sub>sc</sub> (0-72h) [L/h]	CL <sub>sc</sub> (0-336h) [L/h]	CL <sub>sc</sub> (0- $\infty$ ) [L/h]	
Volunteer 1	715	1,0	*	*	19083	#	19083	3084	1048	1048
Volunteer 2	2970	0,7	*	*	125405	*	*	428	159	*
Volunteer 3	3738	1,0	*	*	30141	*	*	1719	663	*
Volunteer 4	2916,	1,0	*	*	3049	#	3049	6559	6559	6559
Volunteer 5	593	18,0	*	*	7161	#	7161	2792	2792	2792
Volunteer 6	660	1,0	*	*	20984	#	20984	2739	953	953
Volunteer 7	1028	2,0	*	*	4533	#	4533	4411	4411	4411
Volunteer 8	959	2,0	*	*	2552	#	2552	7836	7836	7836
Volunteer 9	368	10,0	*	*	66726	*	*	1510	299	*
Volunteer 10	447	2,0	*	*	58115	*	*	890	344	*
Volunteer 11	307	336,0	*	*	85601	*	*	1429	233,	*
Volunteer 12	188	0,3	*	*	39024	*	*	2585	512	*
Volunteer 13	283	12,0	*	*	18971	*	*	4588	1054	*
Volunteer 14	222	1,5	*	*	1400	#	1400	14279	14279	14279
Volunteer 15	250	8,0	*	*	37028	*	*	2432	540	*

\*no determination possible due to non-linear run of curve; # no extrapolation necessary since serum concentration decreased to or below predose values within the time period of blood sampling

**Table 4: Safety laboratory parameters: Difference from before to 14 ± 3 days after subcutaneous application of 1ml abnobaVISCUM® Fraxini 20mg (n=15)**

Parameter	Lower Quartile	Median	Upper Quartile	Lower Limit 95% CI	Upper Limit 95% CI
Hemoglobin (g/dl)	-0.9	-0.2	0	-1.5	1.4
White blood count / $\mu$ l	70	640	1220	-990	2680
Platelet count / $\mu$ l	58000	108000	136000	3000	18000
Creatinine (mg/dl)	0	0	0.1	-0.1	0.3
Uric acid (mg/dl)	-0.3	0.3	0.9	-1.0	1.2
Sodium (mmol/l)	-1	1	2	-5	3
Potassium (mmol/l)	0.1	0.3	0.7	-0.3	1.2
Calcium (mmol/l)	0	0.1	0.2	0	0.3
Creatinkinase (U/l)	-39	1	19	-80	119
Alanine aminotransferase (U/l)	1	5	20	-5	31
Aspartate aminotransferase (U/l)	-1	2	4	-6	11
Lactate dehydrogenase (U/l)	11	22	27	-10	48
Gamma glutamyltransferase (U/l)	0	3	8	-2	30
Bilirubin (mg/dl)	-0.3	-0.1	0	-1.3	0.4
Alpha amylase (mg/dl)	-2	4	11	-5	25
Total protein (g/dl)	0	0.5	0.8	-0.4	1.2
Albumin (g/dl)	-0.1	0.4	0.6	-0.4	0.9
C-reactive protein (mg/dl)	0	0.2	0.5	0	0.7
Cholesterol (mg/dl)	-7	2	14	-35	32
Triglycerides (mg/dl)	-19	5	52	-62	103
Glucose (mg/dl)	-3	-1	4	-4	21




Figure 1: Individual natural mistletoe lectin concentration-time profiles (n=15)




Figure 2: Arithmetic mean of sublingual body temperature after (n=15)